MedTrace Logo

Effectiveness of Hexaminolevulinate (Hexvix) in the Diagnosis and Treatment of Patients With Non-invasive Bladder Cancer

NCT00634621 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 283

Last updated 2014-08-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effectiveness of hexaminolevulinate (Hexvix) in the diagnosis and treatment of patients with non-invasive bladder cancer and if it results in a change in patient management.

Conditions

Interventions

DRUG

Hexaminolevulinate (Hexvix)

Each patient enrolled into the study will be infused with 50 mL of a 2 mg/mL Hexvix solution in the bladder using a catheter. Subsequently, after fluid retention by the patient in the bladder for one hour, the bladder will be emptied.

Sponsors & Collaborators

  • GE Healthcare

    lead INDUSTRY

Principal Investigators

  • Dr. Carlos Hernández · Gregorio Marañón Hospital, Madrid

  • Dr. Eduardo Solsona · Valencian Institute of Oncology, Valencia

  • Dr. Joan Palou · Fundación Puigvert, Barcelona

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00634621 on ClinicalTrials.gov